Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Adcetris

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

AZ and Redx collaborate on genetics of cancer

Research will take place at Alderley Park site

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Major depression in UK cancer patients going untreated

Only 17% of patients reacted to usual NHS therapy according to new research

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

Pfizer to work with genetics firm on bowel disease

Agrees deal with 23andMe to research ulcerative colitis and Crohn’s disease

- PMLiVE

Pfizer closes on $1bn label expansion for Prevenar

EMA begins review of the pneumococcal vaccine

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links